The 7 analysts offering 12-month price forecasts for ProQR Therapeutics NV have a median target of 4.07, with a high estimate of 6.11 and a low estimate of 1.84. The median estimate represents a +135.50% increase from the last price of 1.73.
The current consensus among 8 polled investment analysts is to Buy stock in ProQR Therapeutics NV. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.02
Reporting Date Feb 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.